ArticleBioinformatics advances2026
Multi-DDA: drug-disease association prediction using a hybrid graph convolutional network with multi-modal drug representations.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LNMGAT: a laplacian regularized pseudo-negative mining graph attention network for robust drug-target interaction prediction under multi-scenario cold-start settings.Frontiers in bioinformatics · 2026Article
- A leakage-aware genomic prediction pipeline for meropenem resistance inBioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Predicting drug-disease associations (DDAs) is essential for efficient drug repurposing. Although graph convolutional networks (GCNs) on heterogeneous drug-disease graphs are state-of-the-art, they often underutilize the rich, multi-modal data available for drugs, such as targets, enzymes, pathways, and chemical substructures. Results: To address this, we introduce Multi-DDA, a novel framework that systematically integrates these multi-modal drug features into a dedicated learning branch. These enriched drug descriptors are hierarchically combined with the outputs of each graph convolution layer, allowing subsequent layers to selectively refine the most informative node representations. This multi-modal fusion creates more comprehensive drug and disease embeddings. The representations are then processed by a graph attention layer to weigh the importance of different node connections before a final Multi-Layer Perceptron predicts the association matrix. Evaluated on a benchmark dataset of 269 drugs and 598 diseases, Multi-DDA outperforms seven existing methods across key metrics-Area Under the Precision-Recall Curve (AUPR), Area Under the Receiver Operating Characteristic Curve (AUC), and Recall. The significant gains in AUPR and Recall demonstrate its enhanced capability to identify potential DDAs, offering a powerful tool for advancing personalized medicine and drug discovery. Availability and implementation: The source code for Multi-DDA is freely available at https://github.com/dehghan1401/Multi-DDA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.